NasdaqCM:AMRNBiotechs
Amarin (AMRN) Stock Hinges On Cash Flow As Revenue Retreat Deepens
Amarin stock barely flinched after earnings, ticking up about 0.5% to US$14.23, yet the quarter itself was anything but flat. The market treated this as a routine biotech update. The numbers tell you Q2 was about something bigger.
The headline is the earnings mix. Revenue came in at US$42.2m with Amarin still reporting a loss, but the company generated positive operating cash flow for a third straight quarter and ended June with US$314.6m in cash and investments and no debt. For a loss‑making...